Ventana Biotech Stock Fundamentals
| VNTA Stock | USD 0 0 41.67% |
Ventana Biotech fundamentals help investors to digest information that contributes to Ventana Biotech's financial success or failures. It also enables traders to predict the movement of Ventana Pink Sheet. The fundamental analysis module provides a way to measure Ventana Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ventana Biotech pink sheet.
Ventana |
Ventana Biotech Company Current Valuation Analysis
Ventana Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ventana Biotech Current Valuation | 165.2 K |
Most of Ventana Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ventana Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ventana Biotech has a Current Valuation of 165.2 K. This is 100.0% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Ventana Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ventana Biotech's current stock value. Our valuation model uses many indicators to compare Ventana Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ventana Biotech competition to find correlations between indicators driving Ventana Biotech's intrinsic value. More Info.Ventana Biotech is rated first in current valuation category among its peers. It is rated first in shares outstanding category among its peers creating about 333.33 of Shares Outstanding per Current Valuation. Comparative valuation analysis is a catch-all model that can be used if you cannot value Ventana Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ventana Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ventana Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ventana Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ventana Biotech could also be used in its relative valuation, which is a method of valuing Ventana Biotech by comparing valuation metrics of similar companies.Ventana Biotech is currently under evaluation in current valuation category among its peers.
Ventana Fundamentals
| Current Valuation | 165.2 K | |||
| Shares Outstanding | 55.07 M | |||
| Price To Earning | (1.00) X | |||
| Gross Profit | (260) | |||
| EBITDA | (36.71 K) | |||
| Net Income | (47.08 K) | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (54.01 K) | |||
| Earnings Per Share | (0) X | |||
| Beta | -2.08 | |||
| Market Capitalization | 192.73 K |
About Ventana Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ventana Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ventana Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ventana Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland. Ventana Biotech is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ventana Pink Sheet
Ventana Biotech financial ratios help investors to determine whether Ventana Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ventana with respect to the benefits of owning Ventana Biotech security.